---
figid: PMC2897908__nihms-209662-f0002
figtitle: 'Targeting the MAPK Pathway in Melanoma: Why some approaches succeed and
  other fail'
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC2897908
filename: nihms-209662-f0002.jpg
figlink: /pmc/articles/PMC2897908/figure/F2/
number: F2
caption: Schematic representation of key targets and pharmacological agents that inhibit
  MAPK signaling proteins. Imitanib, dastinib and sorafenib inhibit receptor tyrosine
  kinases thereby preventing activation of mitogen dependent activation in the MAPK
  pathway. Tipifarnib, R115777, BMS-214662 and L-778123 are selective to RAS while
  PLX4032, RAF-265 and XL281 specifically target activated B-RAF and are at various
  stages of clinical development. AZD6244, U0126, PD0325901, CI-1040, XL518, AZD8330,
  ARRY-162 and ARRY-300 inhibit MEK 1/2 while curcumin, plumbagin and DHMEQ target
  IKKβand NFκB.
papertitle: 'Targeting the MAPK Pathway in Melanoma: Why some approaches succeed and
  other fail.'
reftext: Gajanan S Inamdar, et al. Biochem Pharmacol. ;80(5):624-637.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7370867
figid_alias: PMC2897908__F2
figtype: Figure
redirect_from: /figures/PMC2897908__F2
ndex: abebee69-df13-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2897908__nihms-209662-f0002.html
  '@type': Dataset
  description: Schematic representation of key targets and pharmacological agents
    that inhibit MAPK signaling proteins. Imitanib, dastinib and sorafenib inhibit
    receptor tyrosine kinases thereby preventing activation of mitogen dependent activation
    in the MAPK pathway. Tipifarnib, R115777, BMS-214662 and L-778123 are selective
    to RAS while PLX4032, RAF-265 and XL281 specifically target activated B-RAF and
    are at various stages of clinical development. AZD6244, U0126, PD0325901, CI-1040,
    XL518, AZD8330, ARRY-162 and ARRY-300 inhibit MEK 1/2 while curcumin, plumbagin
    and DHMEQ target IKKβand NFκB.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ras
  - Ras64B
  - Ras85D
  - Akt
  - Raf
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - KRAS
  - HRAS
  - NRAS
  - AKT1
  - AKT2
  - AKT3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - plumbagin
  - U0126
  - R115777
  - BMS-214662
  - L-778123
  - PD0325901
  - AZD6244
  - Curcumin
---
